RenovoRx (RNXT) Projected to Post Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is expected to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect RenovoRx to post earnings of ($0.08) per share and revenue of $0.47 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last issued its earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%. The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.42 million. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Trading Down 1.6%

Shares of RenovoRx stock opened at $0.85 on Tuesday. The company has a fifty day simple moving average of $0.94 and a 200-day simple moving average of $0.95. RenovoRx has a 12-month low of $0.70 and a 12-month high of $1.45. The stock has a market cap of $38.29 million, a price-to-earnings ratio of -2.66 and a beta of 1.00.

Hedge Funds Weigh In On RenovoRx

Institutional investors have recently modified their holdings of the business. XTX Topco Ltd grew its position in RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after buying an additional 18,525 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in RenovoRx in the 2nd quarter valued at $98,000. Citadel Advisors LLC purchased a new position in RenovoRx in the 3rd quarter valued at $154,000. Wealthspire Advisors LLC purchased a new position in RenovoRx in the 4th quarter valued at $212,000. Finally, Geode Capital Management LLC grew its position in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares during the last quarter. 3.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RNXT has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of RenovoRx in a report on Wednesday, April 8th. Ascendiant Capital Markets raised their price target on RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Wall Street Zen downgraded RenovoRx from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 4th. Finally, JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, RenovoRx presently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.